The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.
Key Financial Performance
Revenue Third quarter revenue of $137 million increased 23% compared to a year ago, driven by 42% growth in the Pharmacy business and 13% year-over-year growth in the fee-for-service business.
Adjusted EBITDA Adjusted EBITDA loss of $3.5 million in Q3 represents a $4.7 million improvement compared to the same quarter last year.
Capitated Revenue Capitated revenue increased 38.9% year-over-year, contributing to patient services revenue growth.
Pharmacy Revenue Pharmacy revenue was $75.9 million, representing 55.6% of total revenue and increased 57.4% year-over-year due to higher prescription volumes and greater pharmacy attachment within the network.
Gross Profit Gross profit was $18.9 million for the quarter compared to $14.4 million in the third quarter of 2024. Normalized for a $1.8 million reserve adjustment, gross profit would have been $20.7 million.
SG&A Expenses SG&A expenses (excluding depreciation and amortization) were $25.3 million or 18.5% of revenue, down from 26.7% of revenue a year ago, reflecting cost discipline and technology efficiencies.
Cash Flow from Operations Cash flow from operations was negative $27.8 million, improving 9.5% from the prior year, reflecting investments in drug inventory and working capital to support scaling dispensing activity.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Florida Pharmacy Opening: The official opening of the TOI Florida pharmacy location, which will serve network providers requiring delivery of Part B drugs and provide a fast and convenient option for Part B specialty medications for patients and providers.
AI Enablement Efforts: Launched three AI enablement efforts in revenue cycle management, prior authorization services, and patient call center. Transition to agentic AI model expected to reduce submission time from 18 minutes to 5 seconds, saving over 80% per authorization and yielding up to $2 million in operating expense efficiencies.
Expansion in Florida: Expanded partnership with Elevance Health in Florida, doubling Medicare Advantage lives under capitation in less than a year. MSO network in Florida grew to over 200 providers.
Capitation Revenue Growth: New capitation contracts signed across markets in 2025 will contribute an estimated $19 million in full-year revenue, a 29% increase compared to 2024.
MLR Performance: Achieved strong MLR performance on the delegated capitation model in Florida, managing 40,000 lives. Expanded relationship with Elevance Health to include additional Medicare Advantage lives.
Operational Efficiencies: SG&A expenses reduced to 18.5% of revenue, down from 26.7% a year ago, reflecting cost discipline and technology efficiencies.
Value-Based Care Model: Proven ability to manage full delegation with health plan partners, opening new opportunities for value-based contract growth.
Cybersecurity Incident Management: Managed a cybersecurity incident with minimal disruption to operations, ensuring patient treatment plans remained intact and day-to-day operations continued smoothly.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cybersecurity Incident: A cybersecurity incident at a key vendor disrupted billing and practice management, leading to a temporary inability to bill for fee-for-service claims. This will delay collections into late Q4 and early Q1, potentially impacting cash flow and operational efficiency.
New Capitation Contracts: Margins on new capitation contracts are initially low and will take time to mature, which could impact short-term profitability and financial performance.
Fee-for-Service Revenue: A $1.8 million reserve was recorded against fee-for-service revenue due to potential future bad debt, reflecting caution but also impacting gross profit margins.
Convertible Debt: The company has $86 million in convertible debt maturing in 2027, which could pose financial risks if not managed effectively.
Scaling and Drug Inventory Investments: Negative cash flow from operations, driven by investments in drug inventory and working capital, could strain liquidity as the company scales its dispensing activity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company has raised its full-year revenue guidance for 2025 from $460 million to $480 million to a new range of $495 million to $505 million.
Adjusted EBITDA Guidance for 2025: The company has raised the lower end of its adjusted EBITDA guidance for 2025 from a loss of $17 million to $8 million to a new range of a loss of $13 million to $11 million. This implies adjusted EBITDA between breakeven and positive $2 million for the fourth quarter.
Profitability Expectations: The company expects to achieve adjusted EBITDA profitability in the fourth quarter of 2025 and become free cash flow positive in 2026.
Capitation Revenue Growth: New capitation contracts signed in 2025 are expected to contribute an estimated $19 million in full-year revenue, representing a 29% increase in capitated revenue compared to 2024.
Margins on New Capitation Contracts: Margins on new capitation contracts are expected to mature to target levels over the next few quarters as patients transition to in-network providers and adherence to care pathways improves.
AI Enablement Efforts: The company plans to fully transition its offices and authorizations to an AI model in Q4 2025, reducing submission time from 18 minutes to 5 seconds and delivering over 80% savings per authorization. This initiative is expected to expand to other functions in 2026, potentially yielding $2 million in operating expense efficiencies.
Impact of Cybersecurity Incident: A cybersecurity incident at a key vendor is expected to influence collections in late Q4 2025 and early Q1 2026, but the company projects sufficient cash to meet operating goals for Q4 2025 and 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you describe the $1.8 million reserve impact on cost of goods and its inclusion in adjusted EBITDA?
A:The $1.8 million reserve to fee-for-service revenue directly impacted adjusted EBITDA and was included in the reported figures. The normalized performance was significantly better than reported.
Q:How sustainable is the first month of profitability in September, and is breakeven EBITDA expected for Q4?
A:The first month of profitability in September is sustainable, and breakeven EBITDA is fully expected for Q4. Full-year positive adjusted EBITDA is anticipated by 2026.
Q:Will there be positive free cash flow in Q4 of 2025?
A:Yes, free cash flow will be positive in Q4 of 2025, with run-rate free cash flow positivity expected by mid-2026.
Q:Can you provide more details on the delegated contract and MLR?
A:The overall MLR for TOI across all markets and contract types is in the high 60s, with the delegated model being slightly higher (mid-70s) and the narrow network model being slightly better. The delegated model has a greater TAM and is expected to contribute more to growth and gross profit long-term.
Q:Why is TOI able to manage trends better than other MA plans?
A:TOI's unique care delivery model, which includes employee clinics and a wrap network of non-employee providers, provides greater control over care consistency, adherence to NCCN guidelines, and prescribing patterns, driving better value for patients and payers.
Q:What drove the 60% year-over-year growth in dispensing revenue?
A:The growth was driven by efforts to minimize leakage in script attachment, achieving levels beyond expectations. However, similar sequential growth is not expected in Q4.
Q:Why was there a sudden need to change the reserve for receivables?
A:The change was a proactive and standard measure due to the substantial fee-for-service revenue. It is not considered out of the ordinary.
Q:What will be the impact of the reserve change on Q4, and can most receivables be recovered?
A:There will be no impact on Q4, and the reserve will remain on the books out of conservatism. Recovery of receivables is not forecasted at this point.
Q:How will changes like Cigna eliminating drug rebates and CMS removing prior authorizations impact TOI's business?
A:These changes are expected to lower drug costs and simplify reimbursement processes, which are net positive for TOI. Specific changes like Cigna's prior auth change may accelerate care delivery but will not significantly impact TOI directly.
Q:What is the current PMPM trend on new contracts, and how does it compare to a year ago?
A:PMPM depends on the population's location and market benchmark spend. Contracts have PMPM escalators, ensuring annual increases. Despite rapid growth in capitated business, MLR has remained stable.
Q:What is TOI's observation on Pluvicto adoption in California clinics, and are there plans to offer it in Florida clinics?
A:TOI has seen increased patient requests and strong adoption of Pluvicto in California clinics. Plans are in place to expand its offering to Florida clinics as use cases grow.
Q:What are the pipeline prospects for new contracts, covered lives, and territories?
A:TOI expects top-line growth of 20%+ with subtle gross margin improvement and flat SG&A as a percentage of revenue. There is continued interest in value-based contracting across markets.
Q:How much of the $50 million annualized value from new contracts has been recognized, and what can be expected for 2026?
A:Deals launched this year have generated $19 million in revenue, with $10-$15 million left. Additional deals in the pipeline are expected to launch over the next three months and into 2026.
Q:How will ACA changes impact TOI's patient population or business?
A:ACA changes are not expected to significantly impact TOI's patient population or business, as most affected patients are already in capitated arrangements.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the pipeline prospects for new contracts, covered lives, and territories, offering only high-level comments about continued interest and growth opportunities. Additionally, responses to questions about ACA changes and the impact of reserve changes on receivables lacked detailed data or clarity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Elevance
MLR
MSO
TAM
TOI
arrangement
authorization
billing
buy in
claim
combination
date
day
debt
dispensing
drug buy
financials
function
incident
leverage model
margin period
milestone
model Florida
model market
month
network capitation
network provider
oncologist
outlook
overview
partner network
period fee
period service
plan partner
provider network
reserve
saving
script attachment
service capitation
service expectation
strength
treatment
week
TOI Transcript
The Oncology Institute, Inc. (TOI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call demonstrates strong financial performance with improved MLR and profitability in Florida, positive growth in dispensary attachment rates, and significant free cash flow improvements. The Q&A reveals optimism about expanding health plan agreements and leveraging pharmacy networks. Although management was vague about specific health plans, the overall sentiment remains positive due to the company’s strategic growth and profitability in key markets. Despite the lack of market cap data, the positive financial and strategic developments suggest a likely stock price increase.
The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript
Positive3-13
The earnings call summary indicates a positive financial performance with increased revenue, adjusted EBITDA, and free cash flow. The company has raised its revenue and EBITDA guidance for 2025, suggesting confidence in future performance. Although there are risks and uncertainties highlighted, the overall outlook remains positive with expected profitability and cash flow positivity. The strategic initiatives, including AI enablement, are likely to drive future efficiencies. Despite the absence of a market cap, the positive financial metrics and guidance suggest a stock price increase in the 2% to 8% range.
The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.
The Oncology Institute, Inc. (TOI) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights strong financial performance with increased pharmacy revenue and improved gross margins. The Q&A section reveals positive insights on drug pricing reforms and growth in patient lives, despite some vague responses from management. Overall, the company's strategic initiatives and financial metrics suggest a positive outlook, likely boosting the stock price by 2% to 8% over the next two weeks.
TOI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
